Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000903423-16-001048
Filing Date
2016-05-16
Accepted
2016-05-16 16:16:02
Documents
4

Document Format Files

Seq Description Document Type Size
1 wildcat13da4.htm SC 13D/A 145349
2 exhibit6.htm EX-99.6 109507
3 exhibit7.htm EX-7 11871
4 exhibit8.htm EX-8 81514
  Complete submission text file 0000903423-16-001048.txt   349801
Mailing Address 9380 JUDICIAL DRIVE SAN DIEGO CA 92121
Business Address 9380 JUDICIAL DRIVE SAN DIEGO CA 92121 858-210-3700
Sorrento Therapeutics, Inc. (Subject) CIK: 0000850261 (see all company filings)

EIN.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-82540 | Film No.: 161654005
SIC: 8731 Services-Commercial Physical & Biological Research

Mailing Address 888 SEVENTH AVENUE NEW YORK NY 10106
Business Address 888 SEVENTH AVENUE NEW YORK NY 10106 212-468-5100
Wildcat Capital Management, LLC (Filed by) CIK: 0001582384 (see all company filings)

EIN.: 453715536 | State of Incorp.: DE | Fiscal Year End: 1213
Type: SC 13D/A